Johnson & Johnson snares FDA nod for first exon 20-targeted drug in EGFR lung cancer

Just a few short months after Johnson & Johnson’s Janssen unit sent its targeted non-small cell lung cancer drug amivantamab to the FDA, the regulator has come back with a green light—a very specific one. Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in… Read More »

Death, pain and soaring wait lists: How surgery backlogs have become pandemic’s lingering collateral damage

Breadcrumb Trail Links News Health and Wellness Health Canada ‘I have lost a lot of patients on the wait list … Those patients and their families deserve recognition that they are victims of this pandemic, too’ Author of the article: Tom Blackwell Publishing date: May 19, 2021  •  2 days ago  •  6 minute read  • … Read More »

Pandemic boosts increase in students seeking public health degrees

TUCSON, Ariz. — During the pandemic, schools across the country have seen a sudden spike in interest for public health degrees, specifically epidemiology. Whether Dr. Anthony Fauci inspired them or whether people just want to give back, people are quickly signing up to learn more about diseases and how they spread.  Emory’s School of Nursing in… Read More »